AAA screening is a men's-health screen: who benefits, and who doesn't
One ultrasound scan for abdominal aortic aneurysm cuts AAA-related deaths in older men who ever smoked — but not all-cause mortality. The evidence is almost entirely about men, which is why the recommendation is too.
| Group | Value (value) |
|---|---|
| AAA-related mortality | 0.65 (0.57 to 0.74) |
| All-cause mortality | 0.99 (0.98 to 1) |
Abdominal aortic aneurysm (AAA) screening is, in practice, a men's-health screen: a single ultrasound scan reduces deaths from AAA in older men who have ever smoked, and the randomised-trial evidence behind it is almost entirely about men [s1]. The catch, stated honestly, is that screening cuts AAA-specific deaths but has not been shown to reduce deaths from all causes [s2]. That combination — a real, targeted benefit that does not move the biggest number — is what makes AAA a useful case study in what screening can and cannot do.
What an AAA is, and why it is a male problem
The abdominal aorta is the body's main artery through the belly; an aneurysm is a balloon-like enlargement of it, defined as a diameter of 3.0 cm or larger [s1]. Most cause no symptoms until they rupture, which is frequently fatal — the rationale for finding and monitoring them before that happens [s1]. The condition is far more common in men: population studies in men older than 60 have found AAA prevalence ranging from 1.2% to 3.3%, and the prevalence has been falling over the past two decades as smoking has declined [s1].
The sex skew is not incidental to the guidance — it drives it. The U.S. Preventive Services Task Force notes that although its recommendation applies to asymptomatic adults, "the randomized trial evidence focuses almost entirely on men aged 65 to 75 years" [s1]. Interestingly, family history carries more weight through the female line: the odds of developing an AAA are stronger with a female first-degree relative (odds ratio 4.32) than with a male one (odds ratio 1.61) [s1].
What the recommendation actually says
The Task Force stratifies its advice by sex, smoking history and family history [s1]:
- Men aged 65 to 75 who have ever smoked: one-time screening with ultrasonography is recommended — a Grade B recommendation [s1].
- Men aged 65 to 75 who have never smoked: clinicians should selectively offer screening rather than screen everyone — Grade C [s1].
- Women who have never smoked and have no family history: the Task Force recommends against routine screening — Grade D [s1].
- Women aged 65 to 75 who have ever smoked: the current evidence is insufficient to weigh the balance of benefits and harms [s1].
The single scan is exactly that — one-time — and the recommendation is consistent with the Task Force's earlier 2014 guidance [s1].
The benefit, and its honest limit
The evidence for the men's recommendation is solid on its own terms. Pooled across the randomised trials, screening reduced AAA-related mortality with a Peto odds ratio of 0.65 (95% confidence interval 0.57 to 0.74) [s1]. In concrete terms, the number needed to screen was 305 men (95% CI 248 to 411) to prevent one AAA death [s2].
But the same pooled analysis found no effect on all-cause mortality: a relative risk of 0.99 (95% CI 0.98 to 1.00), with no heterogeneity between trials [s1]. This is the number a reader should sit with. Screening genuinely prevents a specific, terrible way to die — a ruptured aorta — but across everything that can kill an older man who ever smoked, the needle on total mortality does not measurably move [s2]. That is not a contradiction; it reflects that men in this group face many competing risks, and that removing one cause does not extend overall survival in a way large trials can detect.
What it means for a reader
The practical shape of the evidence is narrow and clear. The men most likely to benefit are those aged 65 to 75 with a smoking history, for whom a one-time scan is a well-supported, low-burden test [s1]. For never-smoking men the decision is individualised, and for most women without risk factors the balance does not favour screening [s1]. And the benefit, though real, is disease-specific rather than a gain in overall lifespan — a distinction that honest screening advice should never blur [s2].
Because smoking is the dominant modifiable risk factor here, the same population overlaps with those weighing lung-cancer screening with low-dose CT. For the broader picture of why cardiovascular disease drives so much of the male mortality gap, see why men die younger, and for the everyday numbers behind that risk, what your cholesterol numbers mean and measuring blood pressure properly at home.
This article is informational and is not medical advice. Screening decisions should be made with a clinician.
Sources
- Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement — JAMA / U.S. Preventive Services Task Force , December 10, 2019
- Primary Care Screening for Abdominal Aortic Aneurysm: Evidence Report and Systematic Review for the USPSTF — JAMA , December 10, 2019
Why men die younger: what the evidence says about the male mortality gap
US men die at higher rates than women at almost every age. In younger men the gap is driven by injuries, overdose and suicide; in older men by heart disease — with delayed help-seeking a recurring thread.
Osteoporosis in men is under-recognised, and the deadliest fractures fall on them
Men break fewer bones than women but die more often after a hip fracture. No major body recommends screening every man, and the US task force says the evidence is simply not there yet.
The male suicide gap: what the evidence says, and what it doesn't
Men die by suicide two to four times as often as women in most countries. The reasons implicate lower help-seeking and masculine norms — and the interventions tested so far have not been shown to reduce it.
Home blood-pressure monitoring beats the clinic reading — if the cuff is validated
Out-of-office readings predict heart attacks and death better than a clinic measurement, and guidelines now require them to confirm hypertension — but only a validated upper-arm cuff counts.